MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease
Ryan Allway November 16th, 2021 Psychedelics The Company will be initiating a clinical validation study on the use of its proprietary biomarker testing in Alzheimer’s Disease diagnostics VANCOUVER, BC, Nov. 16, 2021 /CNW/ – MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )